STAT44%
Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it? 76%
By Lizzy Lawrence80%
6/23/2026, 1:30:00 AM
BS Summary: This article contains 18 faulty reasoning types, including Hasty Generalization, Appeal to Authority, and Ambiguity (Equivocation), with Biased Writer Voice as the most egregious example at 65.6% saturation with 101 hits. Analysis detected 745 faulty-reasoning hits from 154 analyzed words, generating a BS Score of 67.2% and a BS Rank of 76% (5,444 of 21,887 articles). This article is worse (more manipulative) than 75.10% of the article peer group.
WASHINGTON — Millions of Americans with obesity are eagerly awaiting a powerful new drug from Eli Lilly called retatrutide, which has demonstrated bariatric-surgery levels of weight loss.
Some aren’t even waiting for approval from the Food and Drug Administration, instead racing to acquire it through sketchy means.
But STAT has learned that Eli Lilly and the FDA have allowed one person to gain access to the drug through the FDA’s “compassionate use” program, a pathway that gives patients with serious and immediately life-threatening medical issues access to experimental treatments.
This person was a 79-year-old man at the time the request was made in April, according to three sources familiar with the matter.
Those sources, who requested anonymity due to fear of reprisals, said it drew the interest of top health officials, suggesting the person receiving this drug was well connected.
Speakers
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.